(1) In one analysis, semaglutide compared with placebo significantly improved the KCCQ-CSS (mean difference 7.5 points), 6MWD (mean between-group difference 17.1 m), and the hierarchical composite endpoint (win ratio 1.65) and reduced C-reactive protein levels and body weight compared with placebo (all P < 0.0001) and its efficacy was consistent across multiple subgroups.35 (2) Another secondary analysis evaluated whether the effects of semaglutide differ in patients with and without AF (and across various AF types).36 Semaglutide led to larger improvements in the KCCQ-CSS (11.5 vs. The gene discussed is CRP; the disease is atrial fibrillation.